Document:

Prepared by R.R. Donnelley Financial -- Amendment No. 2 To Asset Purchase Agreement

 Exhibit 10.80 
  
 AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT 
  
 This AMENDMENT NO. 2 (this
“Amendment”) is made as of the 17th day of July, 2002, by and between Immunex Corporation, a Washington corporation (“Seller”), and Schering Aktiengesellschaft, a stock corporation organized under the laws of The
Federal Republic of Germany (“Purchaser”). 
  
 WITNESSETH 
  
 WHEREAS, in accordance with Section 7.3 of the Asset Purchase Agreement, dated as of May 2, 2002, by and between Seller and Purchaser (as
amended by Amendment No. 1 to the Asset Purchase Agreement, dated as of June 25, 2002, the “Agreement”), the parties hereto desire to amend the Agreement in certain respects as set forth herein. 
  
 NOW, THEREFORE, in consideration of the premises, covenants, representations and warranties contained herein, the parties hereto,
intending to be legally bound, agree as follows: 
  
 SECTION
1.  Definitions.    Capitalized terms used but not otherwise defined herein shall have the respective meanings set forth in the Agreement, as amended hereby. 
  

SECTION 2.  Amendments to the Agreement.    The Agreement is hereby amended as follows: 
  
 (a)  Section 1.1(a)(viii) of the Seller Disclosure Letter is hereby amended by adding a new item 12 thereunder
as follows: “Agreement, dated as of March 1, 1994, between Behringwerke AG and Immunex Corporation”. 
  
 (b)  Section 1.1(c) of the Seller Disclosure Letter is hereby amended by adding a new item 64 thereunder as follows: “Agreement, dated as of March 1, 1994, between Behringwerke AG and Immunex Corporation”.

  
 (c)  Section 2.1(a)(iii) of the Seller Disclosure Letter is hereby amended by adding
the following item thereto: “Revco -70C chest freezer, model #ULT740ANR, serial #XY1756A, Abbott K #K4269”. 
  
 (d)  Section 3.8(a)(iv) of the Seller Disclosure Letter is hereby amended by adding a new item 8 thereunder as follows: “Agreement, dated as of March 1, 1994, between Behringwerke AG and Immunex
Corporation”. 
 

  
 (e)  Section 2.1(a)(iv) of the Seller Disclosure Letter
is hereby amended by inserting the following new assigned trademark under the table “Assigned Trademarks”: 
  
 
	 United States
 	    	 Positive Directions
 	    	 N/A
 	    	 N/A
 

 
  
 (f)  Exhibit C to the Agreement is hereby
amended by inserting the following new assigned trademark under the table “Assigned Trademarks” in Attachment I to Exhibit C: 
  
 
	 United States
 	    	 Positive Directions
 	    	 N/A
 	    	 N/A
 

 
  
 (g)  Exhibit F to the Agreement is hereby
amended by deleting Annexes A and B thereto and substituting therefor Annex A and Annex B attached hereto as Appendix A. 
  
 SECTION 3.  Effect.    Except as expressly set forth herein, the Agreement shall remain in full force and effect in all respects. This Amendment shall be deemed to be part of the
Agreement for all purposes, including Article IX of the Agreement. 
  
 SECTION
4.  Descriptive Headings.    The descriptive headings herein are inserted for convenience only and are not intended to be part of or to affect the meaning or interpretation of this Amendment. 

 
 SECTION 5.  Counterparts.    This Amendment may be executed in
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties hereto and delivered to
the other party. 
  
 [Signature page to follow] 
  
 

 2 

  
 IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the
date first above written. 
  
 
	 IMMUNEX CORPORATION
 
	 
	 By:
 	 	 /s/    EDWARD V.
FRITZKY        
 

	  	 	 Edward V. Fritzky
 Chief
Executive Officer
 

 
  
  
 
	 SCHERING AKTIENGESELLSCHAFT
 
	 
	 By:
 	 	 /s/    HORST
KRUEGER        
 

	  	 	 Horst Krueger
 General
Counsel
 

 
  
  
 
	 
	 By:
 	 	 /s/    NICHOLAS VON
BEHR       
 

	  	 	 Nicholas von Behr
 Legal
Counsel
 

 
 

 3 

  
 Appendix A 
  
 ANNEX A 
  
 
	 Transition Service
 
	 	 Max Period
 
	    	 Max Hours/Month
 
	 	 Contact Person
 (Purchaser/Seller)
 

	 Human Resources/Payroll
 	 	  	    	  	 	  
	 —  Transition support of payroll, benefits and compensation information
 	 	 3 months
 	    	 60
 	 	 —  J. Wayne (Berlex)/ Nancy Bruce (Immunex)
 
	 Process Development & Mfg:
 	 	  	    	  	 	  
	 —  Transition support of process development and manufacturing activities
 	 	 3 months
 	    	 40
 	 	 —  Dave Carlson (Berlex)/Brent Willems and Jim Thomas (Immunex)
 
	 Quality Assurance/Quality Control:
 	 	  	    	  	 	  
	 —  Transition support for raw materials and acquisition and handling
 	 	 3 months
 	    	 20
 	 	 —  M. Graham, G. Oliarnyk (Berlex)/Ken Riker (Immunex)
 
	 —  Transition support for in-process testing and final batch release
 	 	 3 months
 	    	 20
 	 	 —  M. Graham, G. Oliarnyk (Berlex)/Maija Sorenson and Annette Vahratian (Immunex)
 
	 Customer Contracts:
 	 	  	    	  	 	  
	 —  Support transition of customer contracting through contract discussion with management
personnel
 	 	 3 months
 	    	 80
 	 	 —  R. Graybill (Berlex) and R. Crandall (Berlex)/Michael Ambieli and Joyce Golden (Immunex)
 

 
 

 4 

  
 
	 Transition Service
 
	 	 Max Period
 
	    	 Max Hours/Month
 
	 	 Contact Person
 (Purchaser/Seller)
 

	 Marketing:
 	 	  	    	  	 	  
	 —  Support for all existing and ongoing market research studies, forecast databases, and competitive
intelligence databases
 	 	 1 month  
 	    	 60
 	 	 —  Nancy Burns (Berlex)/ Tyler Ellison (Immunex)
 
	 —  Support for all sales training programs
 	 	 1 month  
 	    	 80
 	 	 —  Rob Crandall (Berlex)/ Michael Casarella (Immunex)
 
	 Sales:
 	 	  	    	  	 	  
	 —  Support transition of chargeback processing to Purchaser
 	 	 3 months
 	    	 15
 	 	 —  R. Graybill (Berlex), R. Crandall (Berlex), A. Santini (Berlex) /Kendall Stever (Immunex)
 

 
 

 5 

 
	 Transition Service
 
	 	 Max Period
 
	    	 Max Hours/Month
 
	 	 Contact Person
 (Purchaser/Seller)
 

	 Clinical:
 	 	  	    	  	 	  
	 —  Support transfer of clinical study management to Purchaser for Crohn’s clinical study and
progress study in colorectal cancer
 	 	 3 months
 	    	 125
 	 	 —  Dr. E. Bradley and M. Gilbert (Berlex)/Anne Trench, A. Rubin, M. Bisom, and C.
Foerder (Immunex)
 
	 
	 —  Consultation and support of ProTrack database
 	 	  	    	  	 	  
	 
	 —  Oversight of transfer/installation of controlled records only if requested
 	 	  	    	  	 	  
	 
	 —  Consultation/advisory service for records systems
 	 	  	    	  	 	  
	 
	 —  PPD support to process and forward misdirected clinical specimens to central lab
 	 	  	    	  	 	  
	 
	 —  PPD consulting support for GLP assays
 	 	  	    	  	 	  

 
 

 6 

  
 
	 Transition Service
 
	 	 Max Period
 
	  	 Max Hours/Month
 
	 	     Contact Person     (Purchaser/Seller)
 

	 Safety Reporting:
 	 	  	  	  	 	  
	 —  Support transfer of adverse experience reporting and analysis and maintenance of case data and data
files
 	 	 3 months
 	  	 100
 	 	 —  Dr. H. Krenz (Berlex)/Wayne Jack Wallis (Immunex)
 
	 
	 —  ARISg data entry as needed to input incoming AE’s
 	 	  	  	  	 	  
	 
	 —  Reviewer support for AE coding, determination of drug relationship, follow-up, and case-transfer to
Berlex safety surveillance
 	 	  	  	  	 	  
	 Regulatory:
 	 	  	  	  	 	  
	 —  Support transfer of regulatory and government filing maintenance
 	 	 3 months
 	  	 40
 	 	 —  T. Bourdakis (Berlex) /Lisa Brown (Immunex)
 
	 Commercial Distribution
 	 	  	  	  	 	  
	 —  Finished goods warehousing and distribution
 	 	 1 month
 	  	 N/A
 	 	 —  I. Arshen (Berlex) and J. Vineis (Berlex) / Rich Gaeto (Immunex)
 
	 Finance:
 	 	  	  	  	 	  
	 —  Consultation services for general accounting, cost accounting, account analysis, month end closing and
SAP (FI/CO, etc.)
 	 	 3 months
 	  	 100
 	 	 —  J. Zitelli, J. Gould, L. Wayne (Berlex)/ Kendall Stever, Janet Kautz (Immunex)
 

 
 

 7 

  
 
	 Transition Service
 
	  	 Max Period
 
	  	 Max Hours/Month
 
	    	 Contact Person
 (Purchaser/Seller)
 

	 Information Technology
 	  	  	  	  	    	  
	 —  Provision of information about the existing IT environment, day-to-day operation of the IT system
relating to LEUKINE and technical support for database transfer
 	  	 3 months
 	  	 30
 	    	 —  Dr. B. Spiegel (Berlex) and J. Gould (Berlex)/Carl March (Immunex)
 
	 Software Applications
 	  	  	  	  	    	  
	 —  Access to and consultation services relating to the operation and transfer of content of the Systems
(as defined in Annex C) as they relate to LEUKINE and the Business (as more fully described in Annex C)
 	  	 9 months
 	  	 That number of hours required based on the commercially reasonable efforts of Seller to achieve the objectives as set forth in Annex
C
 	    	 —  G. Oliarnyk, C. Brochard and Dr. B. Spiegel (Berlex) / Carl March(Immunex)
 

 
  
 
	 MONTHLY FEE FOR SELLER SERVICES (Month 1)
 	  	 =
 	    	 $110,625
 
	 MONTHLY FEE FOR SELLER SERVICES (Months 2-3)
 	  	 =
 	    	 $78,125
 

 
  
 Seller Transition Coordinator 
  

Name: Neil McDonnell 
 Telephone: 206-587-0430 
 

 8 

  
 ANNEX B 
  
 
	 Transition Service
 
	  	 Max Period
 
	  	 Max Hours
 
	  	 Contact Person
 

	 Software Applications
 	  	  	  	  	  	  
	 Access to and consultation services related to the operation and transfer of content of the Systems (as more fully described in Annex C)
 	  	 9 months
 	  	 That number of hours required based on the commercially reasonable efforts of Purchaser to achieve the objectives as set forth in Annex C

	  	 —  G. Oliarnyk, C. Brochard and Dr. B. Spiegel (Berlex) / Carl March (Immunex)
 

 
  
 MONTHLY FEE FOR PURCHASER SERVICES     =    $0

  
 Purchaser Transition Coordinator 
  
 Name: Henrik Jochens 
 Telephone: 510-669-4629 
 

 9Prepared by R.R. Donnelley Financial -- Promissory Note

 Exhibit 10.81 
  
 PROMISSORY NOTE 
  
 $1,000,000.00 
  
 1.  Promise to Pay. 
  
 For value received, I, Beth C. Seidenberg (“Staff Member”), a married woman, and I, Paul S. Vogel, husband of Staff Member, promise to pay to the order of Amgen Inc., a Delaware corporation (“Payee”), at its
office at One Amgen Center Drive, Thousand Oaks, CA 91320-1789, the sum of One Million Dollars and No Cents ($1,000,000.00) (the “Principal”), payable in full on the earlier of five (5) years from date of execution of this Note or thirty
(30) days from the date on which Staff Member ceases to be an employee of Payee, whichever first occurs, together with interest on the Principal from the date of this Note until such date as the Note is paid in full. Interest on this Note shall be
computed as set forth below. The interest rate for the period from the date of this Note through December 31, 2002 (the “initial rate”) is 4.00% per annum on the unpaid Principal. After December 31, 2002 the interest rate on this Note
shall change as set forth below. 
  
 2.  Adjustable Interest Rate. 
  
 The interest rate shall be adjusted annually on January 1 of each year (the “Change Date”) so as to equal the average interest
rate designated as the “Introduction Rates” on adjustable rate loans as publicly offered by the banks and savings and loans in California as published by the Los Angeles Times in its Sunday edition. The rate shall be set using the rates
published in the Los Angeles Times on the Sunday immediately preceding the Change Date. In the event that the “Introduction Rates” list is not published in the Los Angeles Times for any reason, then, in such event, the Payee shall
establish the interest rate based on a survey by it of the introductory interest rates on adjustable loans offered by no fewer than five banking institutions located in Southern California that the Payee, in its sole discretion, deems representative
of banking institutions in the Ventura and Los Angeles County areas. Payee shall give Staff Member notice if the interest rate shall be determined using this alternative method. Notwithstanding the foregoing, the interest rate shall never be
increased or decreased on any single Change Date by more than one percentage point from the interest rate for the preceding 12 months. At no time during the term of this Note shall the annual interest rate exceed 7.00% per annum. 

 
 Payee shall deliver or mail to Staff Member a notice of any changes in the adjustable interest rate on this Note and the amount
of the Staff Member’s semi-monthly payroll deductions before the effective date of any change. The notice shall include information required by law to be given to Staff Member and also the title and telephone number of a person who shall answer
any questions Staff Member may have regarding the notice. 
  
 3.  Salary Deduction. 

 
 The interest on this Note shall be payable by semi-monthly deductions from Staff Member’s salary. The amount of such
deductions shall initially be One Thousand Six Hundred Sixty-Six Dollars and Sixty-Seven Cents ($1,666.67) per installment; provided, however, that the manner of payment of this Note shall not be limited to deductions from Staff Member’s
salary. The amount of such deductions shall be adjusted annually concurrently with any adjustment in the interest rate on this Note to ensure that interest to be incurred during the ensuing calendar year shall be paid in twenty-four (24) equal
payments. The first such installment shall be on 04/15/02; the second installment shall be on 04/30/02; and each successive installment shall be on the fifteenth and last days of each 
 

  
 successive month until the Principal is repaid. Payee shall give Staff Member at least seven (7) days
advance notice of any adjustment in the amount of said payroll deductions. Staff Member acknowledges and agrees that by executing this Note, Staff Member agrees to the payroll deductions described in this Note. 
  
 4.  Option to Convert. 
  
 At the end of the term of this Note, Staff Member shall have the option to seek to convert this loan to a loan amortized over an additional five-year period by executing a new Promissory Note at terms
to be mutually agreed upon by Staff Member and Payee. In the event that Staff Member and Payee are unable to reach agreement on such terms, this Note shall become immediately due and payable. 
  

5.  Prepayment. 
  
 Staff Member may prepay without penalty this Note in whole or in part at any time. Any and all payments or prepayments under this Note may be made by Staff Member to Payee at the following address (or such other address as it
designates in writing to Staff Member): 
  
 AMGEN INC. 
 One Amgen Center Drive 
 Thousand Oaks,
California 91320-1789 
  
 Attention: Accounting Manager 
  
 6.  Attorneys’ Fees. 
  
 Staff Member agrees to pay all costs and expenses, including, without limitation, collection agency fees and expenses, reasonable attorneys’ fees, costs of suit and costs of appeal, which Payee
may incur in the exercise, preservation or enforcement of its right, powers and remedies hereunder, or under any documents or instruments securing this Note, or under law. 
  
 7.  Modification of Terms. 
  
 Payee may, with or without notice to Staff Member, cause additional parties to be added to this Note, or release any party to this Note, or revise, extend, or renew the Note, or extend the time for making any installment
provided for by this Note, or accept any installment in advance, all without affecting the liability of Staff Member. Staff Member may not assign or transfer in any manner whatsoever this Note or any of Staff Member’s obligations under this
Note. 
  
 8.  Security Interest. 
  

The purpose of this loan is to purchase a personal residence. Staff Member shall secure this loan by executing and causing to be filed, immediately upon close of
escrow, a trust deed on this residence, commonly known as 831 Country Valley Road, Thousand Oaks, CA 91362 whose property description is as follows: Lot 57 of Tract No. 4256, in the City of Thousand Oaks, County of Ventura, State of California, as
shown on map recorded in Book 111, Page(s) 42 through 63 inclusive, of Maps, in the office of the County Recorder of said County. Except therefrom all oil, gas, minerals and other hydrocarbon substances, lying below a depth of 500 feet, without the
right of surface entry, as reserved in instruments of record. 
  
 9.  Acceleration.

  
 A)  In the event Staff Member fails to pay when due any sums under this Note, then: 

 2 

  
 (1)  the entire unpaid balance of this Note shall, at
the option of the Payee hereof, immediately become due and payable in full and unpaid Principal thereafter shall bear interest at the lesser of the maximum rate permitted by law or at the rate of 7.00% per annum; and 
  
 (2)  Staff Member authorizes Payee to deduct any sums due to Payee under this Note from any monies, including
any wages due, otherwise owing to Staff Member. 
  
 B)  If Staff Member sells the residence which is
purchased with the funds herein provided, this Note shall immediately become due and payable upon the sale of such residence. 
  
 10.  Waiver of Rights by Staff Member. 
  
 Staff Member waives (1) presentment,
demand, protest, notice of dishonor and/or protest and notice of non-payment; (2) the right, if any, to the benefit of, or to direct the application of, any security hypothecated to Payee until all indebtedness of Staff Member to Payee, however
arising, has been paid; and (3) the right to require the Payee to proceed against any party to this Note, or to pursue any other remedy in Payee’s power. Payee may proceed against Staff Member directly and independently of any other party to
this Note, and the cessation of the liability of any other party for any reason other than full payment, or any revision, renewal, extension, forbearance, change of rate of interest, or acceptance, release or substitution of security, or any
impairment or suspension of Payee’s remedies or rights against any other party, shall not in any way affect the liability of Staff Member. 
  
 11.  Obligations of Persons Under this Note. 
  
 If
more than one person signs this Note, each person is fully and personally obligated to keep all of the promises made in this Note, including the promise to pay the full amount owed. Any person who is a guarantor, surety, or endorser of this Note is
also obligated to do these things. Any person who takes over these obligations, including the obligations of a guarantor, surety or endorser of this Note, is also obligated to keep all of the promises made in this Note. Payee may enforce its rights
under this Note against each person individually or against all of the signatories to this Note. This means that any one of the signatories to this Note may be required to pay all of the amounts owed under this Note. 
  
 12.  Governing Law. 
  
 This Note and the obligations under this Note of Staff Member or any other signatory to this Note shall be governed by and interpreted and determined in accordance with the laws of the State of
California as applied to contracts between California residents entered into and to be performed entirely within said State. 
  
 IN WITNESS WHEREOF, the undersigned has/have executed and delivered this Note as of the 20th day of March, 2002. 
  
 
	 
	 By:
 	 	 /s/    BETH C. SEIDENBERG by
 Paul S. Vogel as her Attorney in Fact        
 

	  	 	 Beth C. Seidenberg
 

 
  
 
	 
	 By:
 	 	 /s/    PAUL S.
VOGEL        
 

	  	 	 Paul S. Vogel
 

 
 

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}]]